Cargando…

Blocking IL-25 signalling protects against gut inflammation in a type-2 model of colitis by suppressing nuocyte and NKT derived IL-13

BACKGROUND: Interleukin-25 (IL-25) is a potent activator of type-2 immune responses. Mucosal inflammation in ulcerative colitis is driven by type-2 cytokines. We have previously shown that a neutralizing anti-IL-25 antibody abrogated airways hyperreactivity in an experimental model of lung allergy....

Descripción completa

Detalles Bibliográficos
Autores principales:	Camelo, Ana, Barlow, Jillian L., Drynan, Lesley F., Neill, Daniel R., Ballantyne, Sarah J., Wong, See Heng, Pannell, Richard, Gao, Wei, Wrigley, Keely, Sprenkle, Justin, McKenzie, Andrew N. J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Japan 2012
Materias:	Original Article—Alimentary Tract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3501170/ https://www.ncbi.nlm.nih.gov/pubmed/22539101 http://dx.doi.org/10.1007/s00535-012-0591-2

Ejemplares similares

Rorα is essential for nuocyte development
por: Wong, See Heng, et al.
Publicado: (2012)

IL23R Variation Determines Susceptibility But Not Disease Phenotype in Inflammatory Bowel Disease
por: Tremelling, Mark, et al.
Publicado: (2007)

Selective expansion of intraepithelial lymphocytes expressing the HLA-E–specific natural killer receptor CD94 in celiac disease()()
por: Jabri*, ‡, §, Bana, et al.
Publicado: (2000)

Clinical characteristics of coronavirus disease (COVID-19) patients with gastrointestinal symptoms: A report of 164 cases
por: Zhang, Hu, et al.
Publicado: (2020)

COVID-19 pandemic perception in adults with celiac disease: an impulse to implement the use of telemedicine
por: Siniscalchi, Monica, et al.
Publicado: (2020)

Impact of COVID-19 outbreak on clinical practice and training of young gastroenterologists: A European survey
por: Marasco, Giovanni, et al.
Publicado: (2020)

COVID-19 in IBD: The experience of a single tertiary IBD center
por: Rizzello, Fernando, et al.
Publicado: (2021)

Impact of the COVID-19 outbreak and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease treated with biologic drugs
por: Bossa, Fabrizio, et al.
Publicado: (2021)

Risk of COVID 19 in patients with inflammatory bowel diseases compared to a control population
por: Maconi, Giovanni, et al.
Publicado: (2021)

Maintaining standard volumes, efficacy and safety, of fecal microbiota transplantation for C. difficile infection during the COVID-19 pandemic: A prospective cohort study
por: Ianiro, Gianluca, et al.
Publicado: (2020)

Anti-SARS-CoV-2 immunoglobulin profile in patients with celiac disease living in a high incidence area
por: Elli, Luca, et al.
Publicado: (2022)

Impact of COVID-19 pandemic on the management of paediatric inflammatory bowel disease: An Italian multicentre study on behalf of the SIGENP IBD Group
por: Arrigo, Serena, et al.
Publicado: (2021)

Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: Data from ESCAPE-IBD, an IG-IBD study
por: Macaluso, Fabio Salvatore, et al.
Publicado: (2023)

The natural history of COVID-19 in vaccinated inflammatory bowel disease patients
por: Viazis, N., et al.
Publicado: (2023)

Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis
por: Suzuki, Yasuo, et al.
Publicado: (2013)

Mucosal and faecal neutrophil gelatinase-associated lipocalin as potential biomarkers for collagenous colitis
por: Bakke, Ingunn, et al.
Publicado: (2021)

Food antigen-induced immune responses in Crohn’s disease patients and experimental colitis mice
por: Kawaguchi, Takaaki, et al.
Publicado: (2014)

Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis
por: Suzuki, Yasuo, et al.
Publicado: (2017)

Correlation of mucosal healing endpoints with long-term clinical and patient-reported outcomes in ulcerative colitis
por: Parkes, Gareth, et al.
Publicado: (2023)

Mucin Gene Deficiency in Mice Impairs Host Resistance to an Enteric Parasitic Infection
por: Hasnain, Sumaira Z., et al.
Publicado: (2010)

Tissue-Specific Amino Acid Transporter Partners ACE2 and Collectrin Differentially Interact With Hartnup Mutations
por: Camargo, Simone M.R., et al.
Publicado: (2009)

The association between antigenemia, histology with immunohistochemistry, and mucosal PCR in the diagnosis of ulcerative colitis with concomitant human cytomegalovirus infection
por: Yamawaka, Tsukasa, et al.
Publicado: (2022)

Association of ulcerative colitis symptom severity and proctocolectomy with multidimensional patient-reported outcomes: a cross-sectional study
por: Matsuoka, Katsuyoshi, et al.
Publicado: (2023)

Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity
por: Neill, Daniel R., et al.
Publicado: (2010)

40 Contribution of IL-33 and Nuocyte to Experimental Allergic Dermatitis
por: Imai, Yasutomo, et al.
Publicado: (2012)

A multicenter, retrospective, observational study of the clinical outcomes and risk factors for relapse of ulcerative colitis at 1 year after leukocytapheresis
por: Kobayashi, Taku, et al.
Publicado: (2017)

Adrenomedullin for steroid-resistant ulcerative colitis: a randomized, double-blind, placebo-controlled phase-2a clinical trial
por: Kita, Toshihiro, et al.
Publicado: (2020)

Expression of ATF6 as a marker of pre-cancerous atypical change in ulcerative colitis-associated colorectal cancer: a potential role in the management of dysplasia
por: Hanaoka, Marie, et al.
Publicado: (2017)

Serum Levels of PCSK9 Are Increased in Patients With Active Ulcerative Colitis Representing a Potential Biomarker of Disease Activity: A Cross-sectional Study
por: Marinelli, Carla, et al.
Publicado: (2022)

Novel Orally Administered Recombinant Anti-TNF Alpha Fusion Protein for the Treatment of Ulcerative Colitis: Results From a Phase 2a Clinical Trial
por: Almon, Einat, et al.
Publicado: (2021)

Physician–patient communication affects patient satisfaction in treatment decision-making: a structural equation modelling analysis of a web-based survey in patients with ulcerative colitis
por: Matsuoka, Katsuyoshi, et al.
Publicado: (2021)

First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis—results from a multicenter prospective randomized controlled trial and its post hoc analysis
por: Kobayashi, Taku, et al.
Publicado: (2015)

Complete mucosal healing of distal lesions induced by twice-daily budesonide 2-mg foam promoted clinical remission of mild-to-moderate ulcerative colitis with distal active inflammation: double-blind, randomized study
por: Naganuma, Makoto, et al.
Publicado: (2017)

Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely active ulcerative colitis: a phase 3, double-blind, randomized, placebo-controlled study-(PURSUIT-J study)
por: Hibi, Toshifumi, et al.
Publicado: (2017)

IL-25 Promotes Th2 Immunity Responses in Asthmatic Mice via Nuocytes Activation
por: Wang, Chao, et al.
Publicado: (2016)

Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term low-dose aspirin therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial
por: Sugano, Kentaro, et al.
Publicado: (2011)

Current Practice and Perception of Screening for Medication Adherence in Inflammatory Bowel Disease
por: Trindade, Arvind J., et al.
Publicado: (2011)

Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term non-steroidal anti-inflammatory drug (NSAID) therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial
por: Sugano, Kentaro, et al.
Publicado: (2012)

Attenuation of indomethacin-induced gastric mucosal injury by prophylactic administration of sake yeast-derived thioredoxin
por: Nakajima, Atsushi, et al.
Publicado: (2012)

Excess weight among colorectal cancer survivors: target for intervention
por: Soerjomataram, I., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_2eb2r6jhmc2nc2996ctqlmpdrt